Tenders

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Ingredient Perindopril and Amlodipine, Atc C09bb04 for the Period April 1, 2023 - March 31, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Oxybutinin (Exclusively Dosage Forms Fer/Ist), Atc G04bd04 for the Period 04/01/2023 - 03/31/2025

Open House Drug Discount Agreements Golimumab, Atc L04ab06

Open House Discount Contracts 2023-02

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Edoxaban, Atc B01af03 for the Period April 1St, 2023 - March 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Eslicarbazepine Acetate, Atc N03af04 for the Period April 1St, 2023 - March 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Colecalciferol (Atc Code: A11cc05).

Open House Contracts for Multiple Active Ingredients/Active Ingredient Combinations

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Dornase Alfa (Atc Code: R05cb13).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Sevelamer Hydrochloride (Atc Code: V03ae02).